Dr. Sam Wickline Biography
Samuel A. Wickline is the professor of medicine, physics, biomedical engineering and cell biology and physiology at Washington University. He received a Bachelor of Arts degree from Pomona College, Claremont, CA in 1974 and the M.D. degree from the University of Hawaii School of Medicine, Honolulu, HI, in 1980.
He completed post-doctoral training in Internal Medicine and Cardiology at Barnes Hospital, St. Louis, MO in 1987 and joined the faculty of the School of Medicine in the Cardiovascular Division before becoming Director of the Cardiovascular Division at Jewish Hospital and subsequently co-director of the Cardiovascular Division at Barnes-Jewish Hospital.
Dr. Wickline is the co-director of the Cardiovascular Bioengineering graduate Program at Washington University and a member of the executive faculty of the Institute for Biological and Medical Engineering. Dr. Wickline initiated the Cardiovascular Ultrasound Laboratory in 1987 and the Cardiovascular Magnetic Resonance Laboratories in 1995 at Washington University School of Medicine.
He also initiated a program in molecular imaging in 1994 following the development of a novel nanoparticulate contrast agent useful for multiple imaging modalities that can be targeted to molecular ligands for diagnostic and therapeutic applications.
Recently he established the Washington University “Consortium for Translational Research in Advanced Imaging and Nanomedicine” (C-TRAIN) at the St Louis CORTEX Center devoted to diagnostic and therapeutic development of nanotechnology in concert with corporate and academic partners for broadbased clinical applications.
Dr. Wickline has served as an Established Investigator of the American Heart Association. He is a member of the American Society for Clinical Investigation. He is a founder of Kereos, a local biotech startup company devoted to molecular imaging and targeted therapeutics.
He also directs the “Siteman Center For Cancer Nanotechnology Excellence” at Washington University. He is the author of more than 180 research papers and holds more than 40 issued or filed U.S. patent applications.